References
- International Agency for Cancer ResearchGLOBOCAN 2008 [webpage on the Internet] http://globocan.iarc.frAccessed October 4, 2013
- El-SeragHBHepatocellular carcinomaN Engl J Med2011365121118112721992124
- FornerALlovetJMBruixJHepatocellular carcinomaLancet201237998221245125522353262
- StarleyBQCalcagnoCJHarrisonSANonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connectionHepatology20105151820183220432259
- WilhelmSMCarterCTangLBAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesisCancer Res200464197099710915466206
- WilhelmSCarterCLynchMDiscovery and development of sorafenib: a multikinase inhibitor for treating cancerNat Rev Drug Discov200651083584417016424
- LlovetJMRicciSMazzaferroVSHARP Investigators Study GroupSorafenib in advanced hepatocellular carcinomaN Engl J Med2008359437839018650514
- ChengALKangYKChenZEfficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trialLancet Oncol2009101253419095497
- ChengALKangYKLinDYSunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trialJ Clin Oncol201331324067407524081937
- CainapCQinSHuangWTPhase III trial of linifanib versus sorafenib in patients with advanced hepatocellular carcinoma (HCC)J Clin Oncol201331Suppl 4 Abs 249
- JohnsonPJQinSParkJWBrivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL studyJ Clin Oncol201331283517352423980084
- ZhuAXRosmorducOEvansJSEARCH: a phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with hepatocellular carcinoma (HCC)ESMO Congress2012 Abs 917
- ChengALShenYCZhuAXTargeting fibroblast growth factor receptor signaling in hepatocellular carcinomaOncology2011815–637238022269894
- CasanovasOHicklinDJBergersGHanahanDDrug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumorsCancer Cell20058429930916226705
- BergersGHanahanDModes of resistance to anti-angiogenic therapyNat Rev Cancer20088859260318650835
- LiuLCaoYChenCSorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5Cancer Res20066624118511185817178882
- ChenKFTaiWTLiuTHSorafenib overcomes TRAIL resistance of hepatocellular carcinoma cells through the inhibition of STAT3Clin Cancer Res201016215189519920884624
- TaiWTChengALShiauCWSignal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinomaJ Hepatol20115551041104821354226
- TaiWTShiauCWChenPJDiscovery of novel Src homology region 2 domain-containing phosphatase 1 agonists from sorafenib for the treatment of hepatocellular carcinomaHepatology201459119020123908138
- OuDLShenYCYuSLInduction of DNA damage-inducible gene GADD45beta contributes to sorafenib-induced apoptosis in hepatocellular carcinoma cellsCancer Res201070229309931821062976
- GedalyRAnguloPHundleyJPI-103 and sorafenib inhibit hepatocellular carcinoma cell proliferation by blocking Ras/Raf/MAPK and PI3K/AKT/mTOR pathwaysAnticancer Res201030124951495821187475
- GedalyRAnguloPChenCThe role of PI3K/mTOR inhibition in combination with sorafenib in hepatocellular carcinoma treatmentAnticancer Res20123272531253622753710
- LachenmayerAAlsinetCSavicRWnt-pathway activation in two molecular classes of hepatocellular carcinoma and experimental modulation by sorafenibClin Cancer Res201218184997500722811581
- LiuLPHoRLChenGGLaiPBSorafenib inhibits hypoxia-inducible factor-1α synthesis: implications for antiangiogenic activity in hepatocellular carcinomaClin Cancer Res201218205662567122929805
- ZhaoDZhaiBHeCUpregulation of HIF-2α induced by sorafenib contributes to the resistance by activating the TGF-α/EGFR pathway in hepatocellular carcinoma cellsCell Signal20142651030103924486412
- HikitaHTakeharaTShimizuSThe Bcl-xL inhibitor, ABT-737, efficiently induces apoptosis and suppresses growth of hepatoma cells in combination with sorafenibHepatology20105241310132120799354
- OuDLShenYCLiangJDInduction of Bim expression contributes to the antitumor synergy between sorafenib and mitogen-activated protein kinase/extracellular signal-regulated kinase kinase inhibitor CI-1040 in hepatocellular carcinomaClin Cancer Res200915185820582819737956
- ChiouJFTaiCJWangYHLiuTZJenYMShiauCYSorafenib induces preferential apoptotic killing of a drug- and radio-resistant Hep G2 cells through a mitochondria-dependent oxidative stress mechanismCancer Biol Ther20098201904191319770576
- CoriatRNiccoCChéreauCSorafenib-induced hepatocellular carcinoma cell death depends on reactive oxygen species production in vitro and in vivoMol Cancer Ther201211102284229322902857
- GalmicheAEzzoukhryZFrançoisCBAD, a proapoptotic member of the BCL2 family, is a potential therapeutic target in hepatocellular carcinomaMol Cancer Res2010881116112520647330
- ShiYHDingZBZhouJTargeting autophagy enhances sorafenib lethality for hepatocellular carcinoma via ER stress-related apoptosisAutophagy20117101159117221691147
- LiXFGongRYWangMSorafenib down-regulates c-IAP expression post-transcriptionally in hepatic carcinoma cells to suppress apoptosisBiochem Biophys Res Commun2012418353153622285185
- SonntagRGasslerNBangenJMTrautweinCLiedtkeCPro-apoptotic Sorafenib signaling in murine hepatocytes depends on malignancy and is associated with PUMA expression in vitro and in vivoCell Death Dis20145e103024481444
- CaoMXuYYounJIKinase inhibitor Sorafenib modulates immunosuppressive cell populations in a murine liver cancer modelLab Invest201191459860821321535
- CabreraRAraratMXuYImmune modulation of effector CD4+ and regulatory T cell function by sorafenib in patients with hepatocellular carcinomaCancer Immunol Immunother201362473774623223899
- WangQYuTYuanYSorafenib reduces hepatic infiltrated regulatory T cells in hepatocellular carcinoma patients by suppressing TGF-beta signalJ Surg Oncol2013107442242722833259
- ZhangQBSunHCZhangKZSuppression of natural killer cells by sorafenib contributes to prometastatic effects in hepatocellular carcinomaPLoS One201382e5594523409093
- SprinzlMFReisingerFPuschnikASorafenib perpetuates cellular anticancer effector functions by modulating the crosstalk between macrophages and natural killer cellsHepatology20135762358236823424039
- ChenMLYanBSLuWCSorafenib relieves cell-intrinsic and cell-extrinsic inhibitions of effector T cells in tumor microenvironment to augment antitumor immunityInt J Cancer2014134231933123818246
- ChenYHuangYReibergerTDifferential effects of sorafenib on liver versus tumor fibrosis mediated by stromal-derived factor 1 alpha/C-X-C receptor type 4 axis and myeloid differentiation antigen-positive myeloid cell infiltration in miceHepatology20145941435144724242874
- OgasawaraSKanaiFObiSSafety and tolerance of sorafenib in Japanese patients with advanced hepatocellular carcinomaHepatol Int20115385085621484134
- Di CostanzoGGTortoraRIodiceLSafety and effectiveness of sorafenib in patients with hepatocellular carcinoma in clinical practiceDig Liver Dis201244978879222579445
- IavaroneMCabibboGPiscagliaFSOFIA (SOraFenib Italian Assessment) study groupField-practice study of sorafenib therapy for hepatocellular carcinoma: a prospective multicenter study in ItalyHepatology20115462055206321898496
- EbosJMLeeCRCruz-MunozWBjarnasonGAChristensenJGKerbelRSAccelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesisCancer Cell200915323223919249681
- SaccoRBargelliniIGinanniBLong-term results of sorafenib in advanced-stage hepatocellular carcinoma: what can we learn from routine clinical practice?Expert Rev Anticancer Ther201212786987522845401
- LencioniRKudoMYeSLGIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib): second interim analysisInt J Clin Pract201468560961724283303
- NakanoMTanakaMKuromatsuREfficacy, safety, and survival factors for sorafenib treatment in Japanese patients with advanced hepatocellular carcinomaOncology201384210811423147476
- ShinginaAHashimAMHaqueMIn a ‘real-world’, clinic-based community setting, sorafenib dose of 400 mg/day is as effective as standard dose of 800 mg/day in patients with advanced hepatocellular carcimona, with better tolerance and similar survivalCan J Gastroenterol201327739339623862169
- KudoMUeshimaKArizumiTReal-life clinical practice with sorafenib in advanced hepatocellular carcinoma: a single-center experienceDig Dis201230660961623258103
- Abou-AlfaGKSchwartzLRicciSPhase II study of sorafenib in patients with advanced hepatocellular carcinomaJ Clin Oncol200624264293430016908937
- Abou-AlfaGKAmadoriDSantoroASafety and efficacy of sorafenib in patients with Hepatocellular Carcinoma (HCC) and Child-Pugh A versus B cirrhosisGastrointest Cancer Res201142404421673874
- PressianiTBoniCRimassaLSorafenib in patients with Child-Pugh class A and B advanced hepatocellular carcinoma: a prospective feasibility analysisAnn Oncol201324240641123041587
- RimassaLPressianiTBoniCA phase II randomized dose escalation trial of sorafenib in patients with advanced hepatocellular carcinomaOncologist201318437938023580239
- HollebecqueACattanSRomanoOSafety and efficacy of sorafenib in hepatocellular carcinoma: the impact of the Child-Pugh scoreAliment Pharmacol Ther201134101193120121958438
- WörnsMAWeinmannAPfingstKSafety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosisJ Clin Gastroenterol200943548949519247201
- PinterMSieghartWGraziadeiISorafenib in unresectable hepatocellular carcinoma from mild to advanced stage liver cirrhosisOncologist2009141707619144684
- OzenneVParadisVPernotSTolerance and outcome of patients with unresectable hepatocellular carcinoma treated with sorafenibEur J Gastroenterol Hepatol20102291106111020300004
- WörnsMAKochSNiederleIMThe impact of patient and tumour baseline characteristics on the overall survival of patients with advanced hepatocellular carcinoma treated with sorafenibDig Liver Dis201345540841323182599
- KimHYParkJWJooJWorse outcome of sorafenib therapy associated with ascites and Child-Pugh score in advanced hepatocellular carcinomaJ Gastroenterol Hepatol201328111756176123800278
- KøstnerAHSorensenMOlesenRKGrønbækHLassenULadekarlMSorafenib in advanced hepatocellular carcinoma: a nationwide retrospective study of efficacy and tolerabilityScientific World Journal2013201393197223431262
- PawlikTMReyesDKCosgroveDKamelIRBhagatNGeschwindJFPhase II trial of sorafenib combined with concurrent transarterial chemoembolization with drug-eluting beads for hepatocellular carcinomaJ Clin Oncol201129303960396721911714
- ParkJWKohYHKimHBPhase II study of concurrent transarterial chemoembolization and sorafenib in patients with unresectable hepatocellular carcinomaJ Hepatol20125661336134222314421
- SieghartWPinterMReiseggerMConventional transarterial chemoembolisation in combination with sorafenib for patients with hepatocellular carcinoma: a pilot studyEur Radiol20122261214122322215073
- ChungYHHanGYoonJHInterim analysis of START: Study in Asia of the combination of TACE (transcatheter arterial chemoembolization) with sorafenib in patients with hepatocellular carcinoma trialInt J Cancer2013132102448245823129123
- SansonnoDLaulettaGRussiSConteducaVSansonnoLDammaccoFTransarterial chemoembolization plus sorafenib: a sequential therapeutic scheme for HCV-related intermediate-stage hepatocellular carcinoma: a randomized clinical trialOncologist201217335936622334456
- KudoMImanakaKChidaNPhase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinomaEur J Cancer201147142117212721664811
- LencioniRLlovetJMHanGSorafenib or placebo in combination with transarterial chemoembolization (TACE) with doxorubicin-eluting beads (DEBDOX) for intermediate-stage hepatocellular carcinoma (HCC): phase II, randomized, double-blind SPACE trialJ Clin Oncol201230Suppl 4 Abs LBA154
- HsuCPo-Ching-LiangMoritaSHuFCChengALPerspectives on the design of clinical trials combining transarterial chemoembolization and molecular targeted therapyLiver Cancer201213–416817624159581
- ShenYCLinZZHsuCHHsuCShaoYYChengALClinical trials in hepatocellular carcinoma: an updateLiver Cancer201323–434536424400222
- VillanuevaAHernandez-GeaVLlovetJMMedical therapies for hepatocellular carcinoma: a critical view of the evidenceNat Rev Gastroenterol Hepatol2013101344223147664
- News Room on March 11, 2014Bayer and Onyx report Phase 3 study results of NEXAVAR® (sorafenib) as adjuvant treatment for patients with liver cancer who have undergone surgery or local ablation [webpage on the Internet] Available from: http://pharma.bayer.com/html/pdf/STORM_Release_FINAL.pdfAssessed March 12, 2014
- Abou-AlfaGKJohnsonPKnoxJJDoxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trialJAMA2010304192154216021081728
- HsuCHShenYCLinZZPhase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinomaJ Hepatol201053112613120416968
- LeeSJLeeJParkSHPhase 1 trial of S-1 in combination with sorafenib for patients with advanced hepatocellular carcinomaInvest New Drugs20123041540154721695438
- Rojas-HernandezCMPattYZFekrazadMHSteinbergKARoachMLeeFCPhase II trial of sorafenib (S) and capecitabine (C) for hepatocellular carcinoma (HCC) in cirrhotic patients (pts)J Clin Oncol201331Suppl 15 Abs e15131
- AssenatEBoigeVThézenasSSorafenib (S) alone versus S combined with gemcitabine and oxaliplatin (GEMOX) in first-line treatment of advanced hepatocellular carcinoma (HCC): Final analysis of the randomized phase II GONEXT trial (UNICANCER/FFCD PRODIGE 10 trial)J Clin Oncol201331Suppl 15 Abs 4028
- YauTCCheungFYLeeFA multicenter phase II study of sorafenib, capecitabine, and oxaliplatin (SECOX) in patients with advanced hepatocellular carcinoma: Final results of Hong Kong-Singapore Hepatocellular Carcinoma Research Collaborative Group studyJ Clin Oncol201331Suppl 15 Abs 4117
- LimHYYenCJTakWYA phase II trial of MEK inhibitor BAY 86-9766 in combination with sorafenib as first-line systemic treatment for patients with unresectable hepatocellular carcinoma (HCC)J Clin Oncol201230Suppl 15 Abs 4103
- ChooSPNgQSChenWJJA phase I/II study of AZD6244 in combination with sorafenib in advanced hepatocellular carcinomaJ Clin Oncol201230Suppl 15 Abs 4100
- FinnRSPoonRTYauTPhase I study investigating everolimus combined with sorafenib in patients with advanced hepatocellular carcinomaJ Hepatol20135961271127723928403
- KelleyRKNimeiriHSMunsterPNTemsirolimus combined with sorafenib in hepatocellular carcinoma: a phase I dose-finding trial with pharmacokinetic and biomarker correlatesAnn Oncol20132471900190723519998
- FaivreSJFartouxLBouattourMA phase I study of AVE1642, a human monoclonal antibody-blocking insulin-like growth factor-1 receptor (IGF-1R), given as a single agent and in combination with sorafenib as first-line therapy in patients with advanced hepato cellular carcinoma (HCC)J Clin Oncol201129Suppl 4 Abs 270
- LeeASZeeBCCheungFYRandomized phase II study of the x-linked inhibitor of apoptosis (XIAP) antisense AEG35156 in combination with sorafenib in patients with advanced hepatocellular carcinoma (HCC)J Clin Oncol201230Suppl 15 Abs 4105
- SunWNelsonDAlbertsSRPhase Ib study of mapatumumab in combination with sorafenib in patients with advanced hepatocellular carcinoma (HCC) and chronic viral hepatitisJ Clin Oncol201129Suppl 4 Abs 261
- ChengALKangYKByooBYPhase Ib dose-escalation study of a phase II randomized trial to assess the safety and tolerability of tigatuzumab (CS-1008) in combination with sorafenib in patients (pts) with advanced hepatocellular carcinoma (HCC)J Clin Oncol201230Suppl 15 Abs e14617
- BitzerMGianniniEGHorgerMEfficacy, tolerability and pharmacokinetics of the oral histone deacetylase inhibitor resminostat in patients with advanced hepatocellular carcinoma: clinical data from the phase II SHELTER studyILCA Annual Conference2012 Abs O-030
- O’NeilBHBendellJCModianoMRPhase I/II study of E7050 (golvantinib) in combination with sorafenib in patients (pts) with advanced hepatocellular carcinoma (HCC): Phase I resultsJ Clin Oncol201331Suppl 4 Abs 294
- MengXWLeeSHDaiHMcl-1 as a buffer for proapoptotic Bcl-2 family members during TRAIL-induced apoptosis: a mechanistic basis for sorafenib (Bay 43-9006)-induced TRAIL sensitizationJ Biol Chem200728241298312984617698840
- RosatoRRAlmenaraJACoeSGrantSThe multikinase inhibitor sorafenib potentiates TRAIL lethality in human leukemia cells in association with Mcl-1 and cFLIPL down-regulationCancer Res200767199490950017909059
- RicciMSKimSHOgiKReduction of TRAIL-induced Mcl-1 and cIAP2 by c-Myc or sorafenib sensitizes resistant human cancer cells to TRAIL-induced deathCancer Cell2007121668017613437
- EzzoukhryZLouandreCTrécherelEEGFR activation is a potential determinant of primary resistance of hepatocellular carcinoma cells to sorafenibInt J Cancer2012131122961296922514082
- Blivet-Van EggelpoëlMJChettouhHFartouxLEpidermal growth factor receptor and HER-3 restrict cell response to sorafenib in hepatocellular carcinoma cellsJ Hepatol201257110811522414764
- ShaoYYHsuCHChengALPredictive biomarkers of antiangiogenic therapy for advanced hepatocellular carcinoma: where are we?Liver Cancer2013229310724159601
- LiMZhaoHZhangXInactivating mutations of the chromatin remodeling gene ARID2 in hepatocellular carcinomaNat Genet201143982882921822264
- GuichardCAmaddeoGImbeaudSIntegrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinomaNat Genet201244669469822561517
- FujimotoATotokiYAbeTWhole-genome sequencing of liver cancers identifies etiological influences on mutation patterns and recurrent mutations in chromatin regulatorsNat Genet201244776076422634756
- HuangJDengQWangQExome sequencing of hepatitis B virus-associated hepatocellular carcinomaNat Genet201244101117112122922871
- KanZZhengHLiuXWhole-genome sequencing identifies recurrent mutations in hepatocellular carcinomaGenome Res20132391422143323788652
- ClearySPJeckWRZhaoXIdentification of driver genes in hepatocellular carcinoma by exome sequencingHepatology20135851693170223728943